(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus c ...

Germany’s Merck KGaA (MRK: DE) today announced the presentation of detailed positive results from Part 1 of the global Phase ...

[Triple-negative breast cancer (TNBC) - closeup view 3d illustration] Nemes Laszlo/iStock via Getty Images Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) announced Saturday that ...

This week's dividend activity included increased payouts from BMO Financial (BMO) and Royal Bank of Canada (RY) as well as ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

Jacobs Solutions is positioned for growth. Read more about the company's robust backlog and strong demand across water, ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

The Texas-based, private equity-backed company that bought DVM Manufacturing LLC and its busy West Chester switchgear factory ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to ...